Risk factors for the development of prostate brachytherapy related urethral strictures

The Journal of Urology
Gregory S MerrickEdward Adamovich

Abstract

We identified clinical, treatment and dosimetric parameters associated with the development of urethral strictures following permanent prostate brachytherapy. From April 1995 through April 2003, 1,186 consecutive patients underwent prostate brachytherapy for clinical stage T1b-T3a NxM0 (2002 American Joint Committee on Cancer) prostate cancer. The treatment plan included supplemental XRT in 625 patients (52.7%) and androgen deprivation therapy in 465 (39.2%). Median followup was 4.3 years. Multiple clinical, treatment and dosimetric parameters were evaluated in univariate and multivariate analyses to identify independent predictors for urethral stricture disease. A total of 29 patients had brachytherapy related urethral strictures. All strictures involved the BM urethra with a 9-year actuarial risk of 3.6% and a median time to development of 2.4 years. The mean radiation dose to the BM urethra was significantly greater in patients with vs without stricture (p = 0.002). On multivariate analysis the BM urethral dose and supplemental XRT predicted urethral stricture. All except 3 patients were successfully treated with urethral dilation or internal optical urethrotomy. Brachytherapy related urethral stricture disease correlates hi...Continue Reading

References

Jan 1, 1997·Radiation Oncology Investigations·G S MerrickH L Walbert
Apr 16, 1998·Der Urologe. Ausg. A·M HeitzF Schreiter
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J ZelefskyS A Leibel
Dec 21, 2000·International Journal of Radiation Oncology, Biology, Physics·W M ButlerB M Hagedorn
Mar 2, 2002·International Journal of Radiation Oncology, Biology, Physics·Gregory S MerrickJonathan H Lief
Nov 7, 2002·International Journal of Radiation Oncology, Biology, Physics·Gregory S MerrickMark L Benson
Nov 20, 2003·Urology·Gregory S MerrickWayne M Butler
Mar 11, 2004·Mayo Clinic Proceedings·Michael J WehleTodd C Igel
May 14, 2005·International Journal of Radiation Oncology, Biology, Physics·Gregory S MerrickZachariah A Allen
Jul 2, 2005·International Journal of Radiation Oncology, Biology, Physics·Zachariah A AllenRobert W Galbreath
Aug 10, 2005·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Kent WallnerWayne Butler

❮ Previous
Next ❯

Citations

Mar 6, 2010·Japanese Journal of Clinical Oncology·Takahiro NoharaMikio Namiki
Aug 3, 2013·The Urologic Clinics of North America·Nathaniel K Ballek, Christopher M Gonzalez
Jul 31, 2012·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·James J EarleyRobert W Laing
Nov 15, 2011·International Journal of Radiation Oncology, Biology, Physics·Eugene ChungPatrick W McLaughlin
Dec 21, 2010·International Journal of Radiation Oncology, Biology, Physics·Nasiruddin MohammedAlavaro Martinez
Nov 16, 2010·The Journal of Urology·Bradley A EricksonBenjamin N Breyer
Sep 10, 2015·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Max PetersMarco van Vulpen
Dec 18, 2007·Seminars in Radiation Oncology·Daniel E Soto, Patrick W McLaughlin
Oct 27, 2007·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·D Peiffert
Feb 8, 2007·Brachytherapy·Kevin LinTimothy D Solberg
Feb 22, 2012·BJU International·Anthony R Mundy, Daniela E Andrich
Apr 8, 2014·Urology·Michael S LeapmanSimon J Hall
Apr 8, 2015·The Journal of Urology·Sascha A AhyaiRoland Dahlem
Dec 30, 2014·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Patricia DíezPeter J Hoskin
Jun 15, 2016·JMIR Research Protocols·Ana Fernandez OtsKomiti Ese Enari
Jul 12, 2016·Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists·Ontida ApinorasethkulAshley Hunzeker
Oct 27, 2016·Der Urologe. Ausg. A·C M RosenbaumL A Kluth
Dec 23, 2016·Der Urologe. Ausg. A·Y Tolkach, G Kristiansen
Sep 13, 2016·Investigative and Clinical Urology·Felix MoltzahnMartin Spahn
May 9, 2014·Current Opinion in Urology·Amanda C ChiChris M Gonzalez
Jun 8, 2017·Therapeutic Advances in Urology·Nicholas R Rocco, Jack M Zuckerman
Jul 1, 2019·International Journal of Urology : Official Journal of the Japanese Urological Association·Akane SekiguchiHiromichi Ishiyama
Jun 8, 2015·Current Opinion in Urology·Jaclyn C Milose, Christopher M Gonzalez
Sep 19, 2020·World Journal of Urology·Connor G PolicastroDmitriy Nikolavsky
Mar 23, 2021·Frontiers in Surgery·Marjan WaterloosNicolaas Lumen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.